Say what? CVS Health execs figure PCSK9 meds to cost up to $150B

Tracy Staton

CVS  is raising eyebrows with a new estimate: A coming class of pricey cholesterol could the U.S. as much as $ 150 billion per year.

FiercePharma News

Share This Post

Related Articles

Leave a Reply

© 2018 Global Regulatory Science. All rights reserved. Site Admin · Entries RSS · Comments RSS